Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1974 Feb;9(2):294–303. doi: 10.1128/iai.9.2.294-303.1974

Development of a Purified Cholera Toxoid I. Purification of Toxin

Ruth S Rappaport 1, Benjamin A Rubin 1, Howard Tint 1
PMCID: PMC414801  PMID: 4205945

Abstract

The enterotoxin from Vibrio cholerae is selectively concentrated from cell-free culture supernatant by co-precipitation with hexametaphosphate and is further purified by adsorption on aluminum hydroxide powder. The bulk of residual somatic antigen becomes insoluble upon lyophilization of the toxin preparation and is removed by centrifugation of the rehydrated material. Other contaminants are eliminated by treatment with activated carbon. Preparations of toxin, purified by this method, have been characterized by: (i) a single immunoprecipitin line against polyvalent antisera; (ii) homogeneity on acrylamide gels; (iii) specific activities on the order of 22 limit-of-bluing doses/μg; (iv) ultraviolet spectra characteristic of pure protein; and (v) overall yields on the order of 50%, irrespective of purification scale. Such preparations, however, have been shown to contain trace amounts of somatic antigen when they are intensively tested either for their ability to elevate serum vibriocidal antibody titers in immunized rabbits or for their ability to increase resistance of immunized mice to live vibrio challenge. In the latter test system, the level of residual somatic antigen per 50 μg of toxin (toxoid) antigen generally did not exceed 0.025% of the Division of Biological Standards reference vaccine, V. cholerae Inaba IN-12. Methods for elimination of this small amount of somatic antigen have been investigated and are discussed. The particular combination of purification steps which are presently described have been easily and reproducibly applied on a production scale to prepare gram amounts of toxin with a high degree of purity, even under a variety of initial conditions.

Full text

PDF
298

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benenson A. S., Mosley W. H., Fahimuddin M., Oseasohn R. O. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull World Health Organ. 1968;38(3):359–372. [PMC free article] [PubMed] [Google Scholar]
  2. Burrows W. Cholera toxins. Annu Rev Microbiol. 1968;22:245–268. doi: 10.1146/annurev.mi.22.100168.001333. [DOI] [PubMed] [Google Scholar]
  3. Craig J. P., Eichner E. R., Hornick R. B. Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males. J Infect Dis. 1972 Mar;125(3):203–215. doi: 10.1093/infdis/125.3.203. [DOI] [PubMed] [Google Scholar]
  4. Craig J. P. Preparation of the vascular permeability factor of Vibrio cholerae. J Bacteriol. 1966 Sep;92(3):793–795. doi: 10.1128/jb.92.3.793-795.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Curlin G. T., Craig J. P., Subong A., Carpenter C. C. Antitoxic immunity in experimental canine cholera. J Infect Dis. 1970 May;121(5):463–470. doi: 10.1093/infdis/121.5.463. [DOI] [PubMed] [Google Scholar]
  6. DAVIS B. J. DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS. Ann N Y Acad Sci. 1964 Dec 28;121:404–427. doi: 10.1111/j.1749-6632.1964.tb14213.x. [DOI] [PubMed] [Google Scholar]
  7. Evans D. J., Jr, Richardson S. H. In vitro production of choleragen and vascular permeability factor by Vibrio cholerae. J Bacteriol. 1968 Jul;96(1):126–130. doi: 10.1128/jb.96.1.126-130.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Finkelstein R. A., Fujita K., LoSpalluto J. J. Procholeragenoid: an aggregated intermediate in the formation of choleragenoid. J Immunol. 1971 Oct;107(4):1043–1051. [PubMed] [Google Scholar]
  9. Finkelstein R. A., LoSpalluto J. J. Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid. J Exp Med. 1969 Jul 1;130(1):185–202. doi: 10.1084/jem.130.1.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. MUSCHEL L. H., TREFFERS H. P. Quantitative studies on the bactericidal actions of serum and complement. I. A rapid photometric growth assay for bactericidal activity. J Immunol. 1956 Jan;76(1):1–10. [PubMed] [Google Scholar]
  12. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  13. ORNSTEIN L. DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY. Ann N Y Acad Sci. 1964 Dec 28;121:321–349. doi: 10.1111/j.1749-6632.1964.tb14207.x. [DOI] [PubMed] [Google Scholar]
  14. Pierce N. F., Greenough W. B., 3rd, Carpenter C. C., Jr Vibrio cholerae enterotoxin and its mode of action. Bacteriol Rev. 1971 Mar;35(1):1–13. doi: 10.1128/br.35.1.1-13.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pierce N. F., Kaniecki E. A., Northrup R. S. Protection against experimental cholera by antitoxin. J Infect Dis. 1972 Dec;126(6):606–616. doi: 10.1093/infdis/126.6.606. [DOI] [PubMed] [Google Scholar]
  16. Richardson S. H., Evans D. G., Feeley J. C. Biochemistry of Vibrio cholerae Virulence I. Purification and Biochemical Properties of PF/Cholera Enterotoxin. Infect Immun. 1970 Jun;1(6):546–554. doi: 10.1128/iai.1.6.546-554.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Richardson S. H. Factors influencing in vitro skin permeability factor production by Vibrio cholerae. J Bacteriol. 1969 Oct;100(1):27–34. doi: 10.1128/jb.100.1.27-34.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Spyrides G. J., Feeley J. C. Concentration and purification of cholera exotoxin by absorption on aluminum compound gels. J Infect Dis. 1970 May;121(Suppl):96+–96+. doi: 10.1093/infdis/121.supplement.s96. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES